Houston, TX

Endocrine and Psychiatry Center

Diabetes Mellitus

Type 1 Diabetes Mellitus

Type 2 Diabetes Mellitus

Overweight

Hypoglycemia

Hypogonadism

Cardiovascular Diseases

Neoplasm Metastasis

Lorcaserin HCl

Avexitide

BELVIQ

LY3209590

Testosterone

Amylyx Pharmaceuticals

Diasome Pharmaceuticals

Eisai

Lilly

Repros Therapeutics

condition

allSponsorName

gender

Male

Female

overallStatus

Recruiting

Not yet recruiting

Active, not recruiting

Enrolling by invitation

Completed

Terminated

Withdrawn

Suspended

Unknown

type

Interventional

Observational

Expanded Access

phase

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Not Applicable

funderTypes

Industry

Other U.S. Federal agency

All others

ageGroup

Child (birth-17)

Adult (18-64)

Older Adult (65+)

AVX-001 (LUCIDITY) is a Phase 3 study to evaluate avexitide compared to placebo in participants with post bariatric hypoglycemia (PBH) related to Roux-en-Y gastric bypass (RYGB). The study will assess avexitide compared to placebo for safety and efficacy, measured by reduction of hypoglycemic events. The study includes a Screening period with a Run-in period (of up to 6- and 3-weeks, respectively); a randomized, double-blind, placebo-controlled study treatment period of 16 weeks; and a two-part open-label extension (OLE) period with a duration of approximately 32 weeks.

Avexitide for Treatment of Post-Bariatric Hypoglycemia

Endocrine and Psychiatry Center | Houston, TX

Site insights

Work at this site?

Active trials

Avexitide for Treatment of Post-Bariatric Hypoglycemia (LUCIDITY)

Trial sponsors